Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Dick's Sporting Goods, Inc. (DKS) Reports In-Line Q4 EPS; Issues Mixed Q1, FY14 Outlook
- Apple (AAPL) Pressures Labels for More Exclusive Music Deals as iTunes Growth Flattens
- American Eagle Outfitters (AEO) Tops Q4 EPS by 1c; Issues Weak Q1 Outlook
- Tesla (TSLA): 'Defending Innovation and Consumer Choice in New Jersey'
- After Hours Stock Movers 3/10 (LJPC) (POWR) (BYD) Higher; (FTEK) (AMZG) (URBN) Lower (more...)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- Pluristem to Present at Barclays and RegenMed Financial Conferences
- Sunshine Heart (SSH) Posts Q4 Loss of 42c/Share; Issues Update
- Regado Biosciences (RGDO) Surges on FDA Fast Track Status for REG1 in PCI
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!